RxDoctor Payments Data

Sean Rea, DO

Family Medicine · Surprise, AZNPI 1982098604

Payments from drug & device makers

$384in general payments, 2019–2025

Across 20 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$173
  • Pfizer$48
  • GSK$37
  • Johnson & Johnson$34
  • AstraZeneca$30
  • Eisai Inc.$22
  • plus $40 from 3 others

What the payments were for

  • Food & beverage$384100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)7$173
Pfizer3$48
GSK2$37
Johnson & Johnson2$34
AstraZeneca2$30
Eisai Inc.1$22
Astellas Pharma US Inc1$15
Novo Nordisk1$14
Gilead1$11

How this compares

$384 in reported general payments places this provider in the 55th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$152,356
Medicare patients
414
Services billed
2,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$85,888
MounjaroTirzepatide58$67,217
EliquisApixaban39$57,330
JardianceEmpagliflozin27$41,509
FarxigaDapagliflozin Propanediol28$29,406
JanuviaSitagliptin Phosphate17$28,920
TrulicityDulaglutide12$18,434
XareltoRivaroxaban14$17,796
MyrbetriqMirabegron12$14,415
Breo ElliptaFluticasone/Vilanterol18$7,135
Atorvastatin Calcium609$6,979
SymbicortBudesonide/Formoterol Fumarate16$6,105
PremarinEstrogens, Conjugated12$5,406
Rosuvastatin Calcium295$5,220
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$4,618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$85,88882 claims
PfizerEliquis, Premarin$48$62,73651 claims
AstraZenecaFarxiga, Symbicort$30$35,51244 claims
Johnson & JohnsonXarelto$34$17,79614 claims
Astellas Pharma US IncMyrbetriq$15$14,41512 claims
GSKBreo Ellipta$37$7,13518 claims
AbbVieSynthroid$173$2,18752 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Surprise

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →